Lai announced positive results from mid-term trial of experimental weight loss drug, with a maximum weight loss of 20.1%.

Leilai Company announced that its experimental obesity treatment drug eloralintide demonstrated significant weight loss effects in Phase II clinical trials, with participants losing between 9.5% and 20.1% of their body weight after 48 weeks. The study evaluated 263 obese or overweight adults with at least one obesity-related comorbidity. All treatment groups achieved the primary endpoint, showing superior weight loss effects compared to the placebo group with only a 0.4% weight loss. The highest dose group achieved the highest average weight loss of 20.1%.